{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:10Z","timestamp":1761894550171},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1007\/s11864-001-0035-3","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T20:43:58Z","timestamp":1183581838000},"page":"217-224","source":"Crossref","is-referenced-by-count":14,"title":["Hairy cell leukemia"],"prefix":"10.1007","volume":"2","author":[{"given":"Lynn","family":"Savoie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"35_CR1","first-page":"2428","volume-title":"Wintrobe\u2019s Clinical Hematology","author":"Johnston JB","year":"1999","unstructured":"Johnston JB: Hairy cell leukemia. In Wintrobe\u2019s Clinical Hematology edn 10. Edited by Lee GR, Foerster J, Lukens J, et al. Baltimore: Lippincott, Williams & Wilkins; 1999:2428\u20132446.","edition":"edn 10"},{"key":"35_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2141.1996.5041045.x","volume":"93","author":"J Mercieca","year":"1996","unstructured":"Mercieca J, Matutes E, Emmett E, et al.: 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996, 93:409\u2013411.","journal-title":"Br J Haematol"},{"key":"35_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.1997.2273044.x","volume":"98","author":"E Matutes","year":"1997","unstructured":"Matutes E, Meeus P, McLennan K, et al.: The significance of minimal residual disease in hairy cell leukemia treated with deoxycoformycin: a long term follow-up study. Br J Haematol 1997, 98:375\u2013383.","journal-title":"Br J Haematol"},{"key":"35_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/1097-0142(19890101)63:1<14::AID-CNCR2820630103>3.0.CO;2-I","volume":"63","author":"BI Dalal","year":"1989","unstructured":"Dalal BI, Freier L, Johnston JB, et al.: Peripheral blood and bone marrow changes following 2\u2019-deoxycoformycin therapy in hairy cell leukemia. Cancer 1989, 63:14\u201322.","journal-title":"Cancer"},{"key":"35_CR5","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V87.4.1556.bloodjournal8741556","volume":"87","author":"S Wheaton","year":"1996","unstructured":"Wheaton S, Tallman MS, Hakmian D, et al.: Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996, 87:1556\u20131560.","journal-title":"Blood"},{"key":"35_CR6","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1002\/1097-0142(19810415)47:8<2066::AID-CNCR2820470827>3.0.CO;2-V","volume":"47","author":"J Jansen","year":"1981","unstructured":"Jansen J, Hermans J: Splenectomy in hairy cell leukemia: a retrospective multicentre analysis. Cancer 1981, 47:2066\u20132076.","journal-title":"Cancer"},{"key":"35_CR7","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/1097-0142(19881201)62:11<2420::AID-CNCR2820621129>3.0.CO;2-I","volume":"62","author":"MJ Ratain","year":"1988","unstructured":"Ratain MJ, Vardiman JW, Barker C, et al.: Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer 1988, 62:2420\u20132424.","journal-title":"Cancer"},{"key":"35_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/1097-0142(19930701)72:1<5::AID-CNCR2820720104>3.0.CO;2-Y","volume":"72","author":"IA Jaiyesimi","year":"1993","unstructured":"Jaiyesimi IA, Kantarjian HM, Estey EH: Advances in therapy for hairy cell leukemia. Cancer 1993, 72:5\u201316.","journal-title":"Cancer"},{"key":"35_CR9","first-page":"89","volume":"14","author":"RT Spielberger","year":"1994","unstructured":"Spielberger RT, Mick R, Ratain MJ, et al.: Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymph 1994, 14(suppl):89\u201393.","journal-title":"Leuk Lymph"},{"key":"35_CR10","first-page":"929","volume":"9","author":"JF Seymour","year":"1995","unstructured":"Seymour JF, Estey EH, Keating MJ, et al.: Response to interferon-a in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995, 9:929\u2013932.","journal-title":"Leukemia"},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","volume":"13","author":"M Grever","year":"1995","unstructured":"Grever M, Kopecky K, Foucar MK, et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study. J Clin Oncol 1995, 13:974\u2013982.","journal-title":"J Clin Oncol"},{"key":"35_CR12","first-page":"1116","volume":"9","author":"KR Rai","year":"1995","unstructured":"Rai KR, Davey F, Peterson B, et al.: Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long term results of study by Cancer and Leukemia Group B. Leukemia 1995, 9:1116\u20131120.","journal-title":"Leukemia"},{"key":"35_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1600-0609.2000.90014.x","volume":"64","author":"EE Damasio","year":"2000","unstructured":"Damasio EE, Clavio M, Masoudi B, et al.: Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur J Haematol 2000, 64:47\u201352.","journal-title":"Eur J Haematol"},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1984.2.12.1336","volume":"2","author":"ASD Spiers","year":"1984","unstructured":"Spiers ASD, Parekh SJ, Bishop MB, et al.: Hairy-cell leukemia: induction of complete remission with pentostatin (2\u2019-deoxycoformycin). J Clin Oncol 1984, 2:1336\u20131342.","journal-title":"J Clin Oncol"},{"key":"35_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1365-2141.1999.01546.x","volume":"106","author":"CE Dearden","year":"1999","unstructured":"Dearden CE, Matutes E, Hilditch BL, et al.: Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999, 106:515\u2013519.","journal-title":"Br J Haematol"},{"key":"35_CR16","first-page":"32","volume":"27","author":"JB Johnston","year":"2000","unstructured":"Johnston JB, Eisenhauer E, Wainman N, et al.: Longterm outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 2000, 27:32\u201336.","journal-title":"Semin Oncol"},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V96.1.71","volume":"96","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, Kopecky KJ, Foucar MK, et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000, 96:2981\u20132298. This multicenter study reviewed the outcome of 241 HCL patients treated with dCF initially or after failure with interferon-alfa. The median duration of follow-up was 9.3 years and, for the 72% of patients achieving a complete response, the 5- and 10-year relapse-free survival rates were 85% and 67%, respectively. There appeared to be no increase in the subsequent rate of second malignancies.","journal-title":"Blood"},{"key":"35_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<352::AID-CNCR15>3.0.CO;2-8","volume":"88","author":"M Rafel","year":"2000","unstructured":"Rafel M, Cervantes F, Beltran JM, et al.: Deoxycoformycin in the treatment of patients with hairy cell leukemia. Cancer 2000, 88:352\u2013357.","journal-title":"Cancer"},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.1998.16.9.3007","volume":"16","author":"BD Cheson","year":"1998","unstructured":"Cheson BD, Sorensen JM, Vena DA, et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998, 16:3007\u20133015.","journal-title":"J Clin Oncol"},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","volume":"92","author":"A Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, et al.: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998, 92:1918\u20131926. This study outlined the long-term follow-up of 349 evaluable patients treated with CdA, demonstrating the long duration of responses and confirming that relapsing patients can be successfully retreated with CdA.","journal-title":"Blood"},{"key":"35_CR21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.1995.13.4.989","volume":"13","author":"G Juliusson","year":"1995","unstructured":"Juliusson G, Heldal D, Hippe E, et al.: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995, 13:989\u2013995.","journal-title":"J Clin Oncol"},{"key":"35_CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10428199609051736","volume":"22","author":"T Robak","year":"1996","unstructured":"Robak T, Blasinska-Morawiec M, Krykowski E, et al.:2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymph 1996, 22:107\u2013111.","journal-title":"Leuk Lymph"},{"key":"35_CR23","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V93.8.2471","volume":"93","author":"A Saven","year":"1999","unstructured":"Saven A, Burian C, Adusumalli J, et al.: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999, 93:2471\u20132477.","journal-title":"Blood"},{"key":"35_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000015204","volume":"84","author":"F Lauria","year":"1999","unstructured":"Lauria F, Bocchia M, Marotta G, et al.: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999, 84:22\u201325. This paper indicates that weekly CdA appears to be as effective and less toxic in HCL as conventional continuous infusion.","journal-title":"Haematologica"},{"key":"35_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1365-2141.1999.01523.x","volume":"105","author":"J Chaski","year":"1999","unstructured":"Chaski J, Murphy C, Duggan C, et al.:Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia. Br J Haematol 1999, 105:1145\u20131146.","journal-title":"Br J Haematol"},{"key":"35_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.1365-2141.1997.3483162.x","volume":"99","author":"O Legrand","year":"1997","unstructured":"Legrand O, Vekhoff A, Marie J-P, et al.:Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects. Br J Haematol 1997, 99:165\u2013167.","journal-title":"Br J Haematol"},{"key":"35_CR27","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","volume":"96","author":"D Genini","year":"2000","unstructured":"Genini D, Adachi S, Chao Q, et al.: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96:3537\u20133543. The investigators in this study evaluated the mechanism of action of the nucleoside analogs, in chronic lymphocytic leukemia cells in vitro, and showed that, while both CdA and dCF damage DNA, CdA is also directly toxic to mitochondria.","journal-title":"Blood"},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.1997.15.5.1803","volume":"15","author":"R Kurzrock","year":"1997","unstructured":"Kurzrock R, Strom SS, Estey E, et al.: Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997, 15:1803\u20131810.","journal-title":"J Clin Oncol"},{"key":"35_CR29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1989.7.2.168","volume":"7","author":"EH Kraut","year":"1989","unstructured":"Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989, 7:168\u2013172.","journal-title":"J Clin Oncol"},{"key":"35_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF02906136","volume":"16","author":"H Hagberg","year":"1999","unstructured":"Hagberg H: Chimeric monoclonal anti-CD20 antibody (rituximab)\u2014an effective treatment for a patient with relapsing hairy cell leukemia. Med Oncol 1999, 16:221\u2013222.","journal-title":"Med Oncol"},{"key":"35_CR31","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V94.10.3340.422k19_3340_3348","volume":"94","author":"RJ Kreitman","year":"1999","unstructured":"Kreitman RJ, Wilson WH, Robbins D, et al.: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999, 94:3340\u20133348.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-001-0035-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0035-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T14:21:27Z","timestamp":1652624487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-001-0035-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s11864-001-0035-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}